1047 related articles for article (PubMed ID: 21683865)
21. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma.
Nik NN; Vang R; Shih IeM; Kurman RJ
Annu Rev Pathol; 2014; 9():27-45. PubMed ID: 23937438
[TBL] [Abstract][Full Text] [Related]
22. Coming into focus: the nonovarian origins of ovarian cancer.
Dubeau L; Drapkin R
Ann Oncol; 2013 Nov; 24 Suppl 8(Suppl 8):viii28-viii35. PubMed ID: 24131966
[TBL] [Abstract][Full Text] [Related]
23. New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications.
Gadducci A; Guerrieri ME; Genazzani AR
Gynecol Endocrinol; 2012 Aug; 28(8):582-6. PubMed ID: 22304686
[TBL] [Abstract][Full Text] [Related]
24. Type-specific cell line models for type-specific ovarian cancer research.
Anglesio MS; Wiegand KC; Melnyk N; Chow C; Salamanca C; Prentice LM; Senz J; Yang W; Spillman MA; Cochrane DR; Shumansky K; Shah SP; Kalloger SE; Huntsman DG
PLoS One; 2013; 8(9):e72162. PubMed ID: 24023729
[TBL] [Abstract][Full Text] [Related]
25. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
26. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Lin DI; Killian JK; Venstrom JM; Ramkissoon SH; Ross JS; Elvin JA
Mod Pathol; 2021 May; 34(5):983-993. PubMed ID: 33077920
[TBL] [Abstract][Full Text] [Related]
27. [Molecular carcinogenesis of ovarian carcinoma].
Diebold J
Verh Dtsch Ges Pathol; 2005; 89():77-83. PubMed ID: 18035676
[TBL] [Abstract][Full Text] [Related]
28. Ovarian cancer risk factors by tumor dominance, a surrogate for cell of origin.
Kotsopoulos J; Terry KL; Poole EM; Rosner B; Murphy MA; Hecht JL; Crum CP; Missmer SA; Cramer DW; Tworoger SS
Int J Cancer; 2013 Aug; 133(3):730-9. PubMed ID: 23364849
[TBL] [Abstract][Full Text] [Related]
29. [Advances in origin and pathogenesis of epithelial ovarian cancer].
Liu CR; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):569-72. PubMed ID: 22169654
[No Abstract] [Full Text] [Related]
30. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics.
Prat J; D'Angelo E; Espinosa I
Hum Pathol; 2018 Oct; 80():11-27. PubMed ID: 29944973
[TBL] [Abstract][Full Text] [Related]
31. Two different, mutually exclusively distributed,
Sukhbaatar N; Bachmayr-Heyda A; Auer K; Aust S; Deycmar S; Horvat R; Pils D
Cold Spring Harb Mol Case Stud; 2017 Jul; 3(4):. PubMed ID: 28679689
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory role of prohibitin in human ovarian epithelial cancer.
Jia L; Ren JM; Wang YY; Zheng Y; Zhang H; Zhang Q; Kong BH; Zheng WX
Int J Clin Exp Pathol; 2014; 7(5):2247-55. PubMed ID: 24966933
[TBL] [Abstract][Full Text] [Related]
33. Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer.
Fujiwara K; McAlpine JN; Lheureux S; Matsumura N; Oza AM
Am Soc Clin Oncol Educ Book; 2016; 35():e247-57. PubMed ID: 27249730
[TBL] [Abstract][Full Text] [Related]
34. Molecular diagnosis in type I epithelial ovarian cancer.
Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
[TBL] [Abstract][Full Text] [Related]
35. New insights into ovarian cancer pathology.
Prat J
Ann Oncol; 2012 Sep; 23 Suppl 10():x111-7. PubMed ID: 22987944
[TBL] [Abstract][Full Text] [Related]
36. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.
Vang R; Shih IeM; Kurman RJ
Adv Anat Pathol; 2009 Sep; 16(5):267-82. PubMed ID: 19700937
[TBL] [Abstract][Full Text] [Related]
37. Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.
Morency E; Leitao MM; Soslow RA
Int J Gynecol Pathol; 2016 May; 35(3):222-9. PubMed ID: 26630225
[TBL] [Abstract][Full Text] [Related]
38. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
[TBL] [Abstract][Full Text] [Related]
39. Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis.
Kurman RJ; Vang R; Junge J; Hannibal CG; Kjaer SK; Shih IeM
Am J Surg Pathol; 2011 Nov; 35(11):1605-14. PubMed ID: 21997682
[TBL] [Abstract][Full Text] [Related]
40. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM
Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]